The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Meeting 2012: Late-Breaking Abstracts Bring Newer Research to the Forefront

ACR/ARHP Annual Meeting 2012: Late-Breaking Abstracts Bring Newer Research to the Forefront

January 1, 2013 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Potential New Drug for Psoriatic Arthritis

Arthur Kavanaugh, MD, professor of clinical medicine and director of the Center for Innovative Therapy in the division of rheumatology, allergy, and immunology at the University of California, San Diego, reported on the results of a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of apremilast (CC-10004) in subjects with active psoriatic arthritis (PALACE 1) study.

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • ACR/ARHP Annual Meeting 2012: New Research Delves Into the Risk of Comorbidities for Patients with Lupus
  • ACR/ARHP Annual Meeting 2012: Fatigue for People with Rheumatoid Arthritis Rooted in Physiological and Psychological Factors
Explore This Issue
January 2013
Also By This Author
  • Optimize Gout Management with the Latest Evidence-Based Guidance

The study included 504 patients with a diagnosis of psoriatic arthritis (PsA) for six months or more treated currently or previously with disease-modifying antirheumatic drugs (DMARDs) or biologics randomized to apremilast (20 mg twice daily; n=168), apremilast (30 mg twice daily; n=168), or placebo (n=168). Patients were excluded from the study if they failed previous treatment with more than three DMARDs or biologic agents or more than one biological TNF inhibitor, or if they had active tuberculosis. Patients were allowed concurrent treatment with stable doses of methotrexate, sulfasalazine, and/or leflunomide.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Overall, 23.6% of patients had received prior biologic treatment, of which 9.3% failed treatment with a biologic agent. Of the 64.9% of patients receiving DMARDs at baseline, most were taking methotrexate (54.2%).

Based on the primary endpoint of achieving ACR20 at Week 16, the study found that significantly more patients treated with apremilast achieved ACR20 than those taking placebo. Compared with 19.4% of patients in the placebo group, 31.3% of patients treated with apremilast (20 mg; P=0.0140) and 41.0% of those treated with apremilast (30 mg; P<0.0001) achieved ACR20 at 16 weeks.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Similar results were seen at 24 weeks, with significantly more patients treated with apremilast achieving ACR50 and ACR70 compared with placebo. Overall, ACR50 was achieved in 4.2% of patients receiving placebo versus 15.3% of patients treated with apremilast (20 mg; P<0.05) and 19.9% of those treated with apremilast (30 mg; P<0.0001), and ACR70 was achieved in 0.6% of the placebo group versus 5.5% in the apremilast (20 mg) group (P<0.05) and 11.2% in the apremilast (30 mg) group (P<0.0001).

The study also found that apremilast was well tolerated, with most adverse events reported across all treatment groups as mild to moderate. The adverse events included diarrhea, nausea, headache, and upper respiratory tract infection. One or more serious adverse events occurred in eight patients on 20 mg apremilast and nine on 30 mg apremilast compared with seven on placebo. According to Dr. Kavanaugh, one patient receiving 20 mg apremilast died, but her death was not thought to be drug related.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: ACR/ARHP Annual Meeting, Psoriatic Arthritis, RA flares, Rheumatoid arthritisIssue: January 2013

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • ACR/ARHP Annual Meeting 2012: New Research Delves Into the Risk of Comorbidities for Patients with Lupus
  • ACR/ARHP Annual Meeting 2012: Fatigue for People with Rheumatoid Arthritis Rooted in Physiological and Psychological Factors
  • ACR/ARHP Annual Meeting 2012: Genes Not the Only Factor in Susceptibility to Rheumatoid Arthritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)